Carmell Historical Income Statement

CTCXW Stock

0.06 0 1.96%

Historical analysis of Carmell Therapeutics income statement accounts such as Depreciation And Amortization of 162.5 K, Interest Expense of 844.9 K or Selling General Administrative of 2.5 M can show how well Carmell Therapeutics performed in making a profits. Evaluating Carmell Therapeutics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Carmell Therapeutics's future profits or losses.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Carmell Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Carmell Therapeutics is a good buy for the upcoming year.

Net Income Gross Profit

Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest.

About Carmell Income Statement Analysis

Carmell Therapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Carmell Therapeutics shareholders. The income statement also shows Carmell investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Carmell Therapeutics Income Statement Chart

Selling General Administrative Other Operating Expenses Research Development Total Operating Expenses Net Income

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Carmell Therapeutics. It is also known as Carmell Therapeutics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Total Operating Expenses

The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.

Net Income

Net income is one of the most important fundamental items in finance. It plays a large role in Carmell Therapeutics financial statement analysis. It represents the amount of money remaining after all of Carmell Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.

Most accounts from Carmell Therapeutics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Carmell Therapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest.

	2010	2022	2023	2024 (projected)
Interest Expense	2.5M	3.7M	889.3K	844.9K
Depreciation And Amortization	242.1K	242.6K	124.8K	162.5K

Interest Expense Depreciation And Amortization

Carmell Therapeutics income statement Correlations

	Net Interest Income	Depreciation And Amortization	Interest Expense	Selling General Administrative	Other Operating Expenses	Operating Income	Net Income From Continuing Ops	Ebit	Research Development	Ebitda	Total Operating Expenses	Reconciled Depreciation	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Gross Profit	Cost Of Revenue
Net Interest Income		-0.87	-1.0	0.22	0.31	-0.37	-0.77	-0.77	0.43	-0.77	0.29	-0.87	-0.77	-0.93	-0.76	-0.57	0.88	-0.88
Depreciation And Amortization	-0.87		0.87	-0.65	-0.72	0.74	0.95	0.96	-0.81	0.96	-0.71	1.0	0.95	0.98	0.95	0.87	-0.98	1.0
Interest Expense	-1.0	0.87		-0.23	-0.31	0.38	0.78	0.77	-0.43	0.77	-0.3	0.87	0.78	0.93	0.77	0.58	-0.88	0.88
Selling General Administrative	0.22	-0.65	-0.23		1.0	-0.98	-0.78	-0.8	0.97	-0.79	1.0	-0.65	-0.78	-0.57	-0.79	-0.93	0.66	-0.66
Other Operating Expenses	0.31	-0.72	-0.31	1.0		-0.99	-0.83	-0.85	0.99	-0.84	1.0	-0.72	-0.83	-0.64	-0.84	-0.95	0.72	-0.72
Operating Income	-0.37	0.74	0.38	-0.98	-0.99		0.87	0.88	-0.98	0.88	-0.99	0.74	0.87	0.69	0.88	0.97	-0.77	0.76
Net Income From Continuing Ops	-0.77	0.95	0.78	-0.78	-0.83	0.87		1.0	-0.89	1.0	-0.82	0.95	1.0	0.95	1.0	0.96	-0.98	0.97
Ebit	-0.77	0.96	0.77	-0.8	-0.85	0.88	1.0		-0.9	1.0	-0.84	0.96	1.0	0.95	1.0	0.97	-0.98	0.98
Research Development	0.43	-0.81	-0.43	0.97	0.99	-0.98	-0.89	-0.9		-0.9	0.99	-0.81	-0.89	-0.73	-0.89	-0.98	0.8	-0.81
Ebitda	-0.77	0.96	0.77	-0.79	-0.84	0.88	1.0	1.0	-0.9		-0.84	0.96	1.0	0.95	1.0	0.96	-0.98	0.98
Total Operating Expenses	0.29	-0.71	-0.3	1.0	1.0	-0.99	-0.82	-0.84	0.99	-0.84		-0.71	-0.82	-0.63	-0.83	-0.95	0.71	-0.71
Reconciled Depreciation	-0.87	1.0	0.87	-0.65	-0.72	0.74	0.95	0.96	-0.81	0.96	-0.71		0.95	0.98	0.95	0.87	-0.98	1.0
Income Before Tax	-0.77	0.95	0.78	-0.78	-0.83	0.87	1.0	1.0	-0.89	1.0	-0.82	0.95		0.95	1.0	0.96	-0.98	0.97
Total Other Income Expense Net	-0.93	0.98	0.93	-0.57	-0.64	0.69	0.95	0.95	-0.73	0.95	-0.63	0.98	0.95		0.95	0.83	-0.99	0.99
Net Income	-0.76	0.95	0.77	-0.79	-0.84	0.88	1.0	1.0	-0.89	1.0	-0.83	0.95	1.0	0.95		0.96	-0.98	0.97
Income Tax Expense	-0.57	0.87	0.58	-0.93	-0.95	0.97	0.96	0.97	-0.98	0.96	-0.95	0.87	0.96	0.83	0.96		-0.89	0.89
Gross Profit	0.88	-0.98	-0.88	0.66	0.72	-0.77	-0.98	-0.98	0.8	-0.98	0.71	-0.98	-0.98	-0.99	-0.98	-0.89		-1.0
Cost Of Revenue	-0.88	1.0	0.88	-0.66	-0.72	0.76	0.97	0.98	-0.81	0.98	-0.71	1.0	0.97	0.99	0.97	0.89	-1.0

Click cells to compare fundamentals

Carmell Therapeutics Account Relationship Matchups

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C

Additional Tools for Carmell Stock Analysis

When running Carmell Therapeutics' price analysis, check to measure Carmell Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Carmell Therapeutics is operating at the current time. Most of Carmell Therapeutics' value examination focuses on studying past and present price action to predict the probability of Carmell Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Carmell Therapeutics' price. Additionally, you may evaluate how the addition of Carmell Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Carmell Historical Income Statement

About Carmell Income Statement Analysis

Carmell Therapeutics Income Statement Chart

Other Operating Expenses

Total Operating Expenses

Net Income

Carmell Therapeutics income statement Correlations

Carmell Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Also Currently Popular

Additional Tools for Carmell Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Tax Provision	Net Interest Income
Depreciation And Amortization	Interest Expense
Selling General Administrative	Total Revenue
Other Operating Expenses	Operating Income
Net Income From Continuing Ops	Ebit
Research Development	Ebitda
Total Operating Expenses	Reconciled Depreciation
Income Before Tax	Total Other Income Expense Net
Net Income	Income Tax Expense
Gross Profit	Cost Of Revenue

Reconciled Depreciation	+ 1.0	Depreciation And Amortization
Cost Of Revenue	+ 1.0	Depreciation And Amortization
Other Operating Expenses	+ 1.0	Selling General Administrative
Total Operating Expenses	+ 1.0	Selling General Administrative
Total Operating Expenses	+ 1.0	Other Operating Expenses
Ebit	+ 1.0	Net Income From Continuing Ops

Cost Of Revenue	- 1.0	Gross Profit
Interest Expense	- 1.0	Net Interest Income
Gross Profit	- 0.99	Total Other Income Expense Net
Total Operating Expenses	- 0.99	Operating Income
Operating Income	- 0.99	Other Operating Expenses
Gross Profit	- 0.98	Net Income